M
Michael Karin
Researcher at University of California, San Diego
Publications - 753
Citations - 246120
Michael Karin is an academic researcher from University of California, San Diego. The author has contributed to research in topics: IκB kinase & Signal transduction. The author has an hindex of 236, co-authored 704 publications receiving 226485 citations. Previous affiliations of Michael Karin include Sanford-Burnham Institute for Medical Research & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Constitutive Baff Signalling Plays a Key Role in CLL Development by Promoting Tumor Cell Survival
Thomas Enzler,Weizhou Zhang,Arnon P. Kater,George F. Widhopf,Carlo M. Croce,Michael Karin,Thomas J. Kipps +6 more
TL;DR: The B cell-activating factor of the tumor necrosis factor family (BAFF) is a potent B-cell survival factor that promotes survival of leukemia cells of patients with chronic lymphocytic leukemia (CLL) cells through activation of the classical NF-kB pathway, and high-level B cell expression of anti-apoptotic proteins are found in TCL1-Tg, as well as MYC-TG mice.
Book ChapterDOI
The JNK Family of MAP Kinases: Regulation and Function
Audrey Minden,Michael Karin +1 more
TL;DR: The SAPKs were identified by virtue of their ability to phosphorylate the N-terminal sites of c-Jun, which is encoded by the c-jun proto-oncogene.
Book ChapterDOI
NF-κB, IκB Kinase and Interacting Signal Networks in Squamous Cell Carcinomas
TL;DR: Recent advances in the understanding of interconnections between NF-κB and IKKs, including IKKα, are summarized in the context of SCC development and progression and as potential target for novel chemotherapy approaches.
Patent
Compositions and methods for gene expression
TL;DR: In this paper, the authors provide nucleotide sequences that mediate one or more functions of IKKα, and methods for using these sequences to identify therapeutic compounds that alter IKK α related pathology.
Patent
Mouse model of crohn’s disease and a method to develop specific therapeutics
TL;DR: In this paper, compositions, transgenic animals and methods for screening and analyzing agents useful for treating inflammatory bowel diseases are presented. But none of them are suitable for the treatment of Crohn's disease.